Top Stories
-
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Topic
-
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Topic
-
Physician-scientist Juanma Schvartzman is a firm believer that his curiosity-driven research on cell metabolism and its influence on cell identity will offer clues for better cancer treatments.
Topic
-
On Sunday, Oct. 6, cancer survivors, researchers, and physicians will cycle through the Hudson Valley to help Columbia solve cancer.
Topic
Latest News
- June 19, 2019
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
Topic
- April 25, 2019
At Columbia, patients with brain cancer will be able to participate in a new type of clinical trial that promises to speed up the development of better drugs for glioblastoma.
Topic
- April 17, 2019
Leading physician and researcher, Lisa Kachnic, MD, will lead Columbia's department of radiation oncology.
Topic
- April 3, 2019
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
- February 20, 2019
A clinical trial at Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
Topic
- February 15, 2019
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
Topic
- January 17, 2019
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
Topic
- December 19, 2018
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
- December 10, 2018
A new study suggests that a type of brain tumor in patients with neurofibromatosis type 1 could be treated with immunotherapy, which has so far proved ineffective in treating most brain cancers.
- December 10, 2018
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
